Network Version
Mitiglinide calcium hydrate Data Sheet
| Product Name: | Mitiglinide calcium hydrate |
 |
|---|---|---|
| CAS No.: | 207844-01-7 | |
| Cat. No.: | HY-B0682A | |
| MWt: | 352.46 | |
| Formula: | C19H24NO3.1/2Ca.H2O | |
| Purity : | >98% | |
| Solubility: | DMSO : 25 mg/mL (ultrasonic);H<sub>2</sub>O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) | |
| Mechanisms: | Target: Metabolic Disease | |
| Biological Activity: | ||
|
Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes[1][2].
IC50 & Target: KATP channel[1]
In Vitro: Mitiglinide calcium hydrate inhibits the Kir6.2/SUR1 channel currents in a dose-dependent manner (IC50 value, 100 nM) but does not significantly inhibit either Kir6.2/SUR2A or Kir6.2/SUR2B channel currents even at high doses (more than 10 μM) in COS-1 cells[1]. In Vivo: Mitiglinide Calcium hydrate (1-3 mg/kg; p.o.) suppresses the increase in plasma glucose levels seen after a meal load and the area under the curve for plasma glucose levels (AUCglucose) up to 5 h after the meal load[2]. |
||
1 Deer Park Dr, Suite F, Monmouth Junction, NJ 08852, USA
Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Web:www.medchemexpress.com